MiT/TFE Family Renal Cell Carcinoma

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The microphthalmia-associated transcription factor/transcription factor E (MiT/TFE) family, including MITF, TFEB, and TFE3, are basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factors.
• These factors, except TFEC, play roles in renal cell carcinoma (RCC) development, particularly in sporadic translocation RCC (tRCC) involving chimeric proteins.
• The germline variant MITF p.E318K is a known RCC risk factor, affecting MITF SUMOylation and transcriptional activity.

Purpose of the Study:

• To review the involvement of MiT/TFE transcription factors in both sporadic and hereditary renal cell carcinoma (RCC).
• To highlight the clinical significance of the MITF p.E318K germline variant in RCC.
• To emphasize the need for recognizing MITF p.E318K RCC and considering germline testing in familial RCC cases.

Main Methods:

• Literature review of studies on MiT/TFE transcription factors and their role in renal cell carcinoma.
• Analysis of reported cases of MITF p.E318K associated RCC.
• Discussion of molecular mechanisms, including SUMOylation, affecting MiT/TFE function in RCC.

Main Results:

• MiT/TFE proteins, often as oncogenic chimeric proteins, are central to sporadic tRCC pathogenesis.
• The MITF p.E318K germline variant is associated with increased RCC risk and altered MITF activity.
• Few cases of MITF p.E318K RCC have been reported, with limited description of their clinical features.

Conclusions:

• MiT/TFE transcription factors are critical oncogenic drivers in various forms of RCC.
• Recognition of MITF p.E318K RCC is important for clinical management and genetic counseling.
• Further research into MiT/TFE family molecular functions is essential for improved diagnosis and treatment of rare RCC subtypes.